Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $369,163.08 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 14,058 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.26, for a total value of $369,163.08. Following the sale, the insider directly owned 76,140 shares of the company’s stock, valued at $1,999,436.40. This represents a 15.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

David Malcom Rodman also recently made the following trade(s):

• On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.37, for a total value of $173,744.76.
• On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.84, for a total value of $58,269.64.
• On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total value of $11,505.03.
• On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.99, for a total value of $184,057.51.
• On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total value of $385,669.20.
• On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.21, for a total value of $65,585.91.
• On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.10, for a total transaction of $13,353.60.
• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total transaction of $252,469.75.
• On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.32, for a total transaction of $205,167.36.

Mineralys Therapeutics Price Performance

MLYS opened at $23.90 on Thursday. Mineralys Therapeutics, Inc. has a fifty-two week low of $10.44 and a fifty-two week high of $47.65. The firm has a market capitalization of $1.97 billion, a P/E ratio of -10.08 and a beta of 0.57. The company’s 50-day moving average is $29.81 and its 200 day moving average is $35.71.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. On average, equities research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Trending Headlines about Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near‑term EPS for Q1–Q3 2026 and bumped its FY2026 estimate (now ($2.14)), while maintaining a “Buy” rating and $56 target — a vote of confidence that can support the stock. HC Wainwright note on MLYS
• Positive Sentiment: Company update: Mineralys reported 2025 results and said it advanced the regulatory review for its hypertension candidate (lorundrostat) — regulatory progress and clinical milestones are key upside catalysts for a clinical‑stage biotech. Mineralys reports 2025 results (MSN)
• Positive Sentiment: Institutional demand: recent 1Q filings show new/expanded positions from AQR, Goldman Sachs, Woodline and others — heavy institutional ownership (≈84%) can amplify moves and indicates investor interest. MLYS institutional holdings
• Neutral Sentiment: Analyst mix and consensus: despite several Buy ratings (6 Buys, 1 Hold, 1 Sell) the street still expects sizeable negative EPS this year (consensus ≈ -4.23), and the consensus target (~$49) remains well above the current price — signals both long‑term upside expectations and near‑term valuation risk. MarketBeat analyst summary
• Negative Sentiment: Insider selling: Director/insider David Malcom Rodman has sold multiple sizable blocks recently (including 6,348 shares on Mar 12), which can be read as near‑term selling pressure or profit‑taking. Insider trades alert
• Negative Sentiment: Offsetting estimate cuts: HC Wainwright trimmed FY2027 and FY2028 EPS forecasts slightly (and nudged Q4 2026 a touch weaker), showing some longer‑horizon uncertainty despite near‑term upgrades — these downgrades add caution for longer‑dated expectations. HC Wainwright detail

Analyst Upgrades and Downgrades

MLYS has been the subject of a number of research analyst reports. Stifel Nicolaus increased their price target on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Wall Street Zen raised Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Bank of America raised their target price on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research note on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Mineralys Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $49.14.

Institutional Investors Weigh In On Mineralys Therapeutics

A number of hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in Mineralys Therapeutics during the first quarter valued at $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Mineralys Therapeutics by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock valued at $271,000 after buying an additional 702 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Mineralys Therapeutics by 166.6% in the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock valued at $4,739,000 after buying an additional 186,480 shares during the period. Woodline Partners LP purchased a new position in shares of Mineralys Therapeutics during the 1st quarter valued at $757,000. Finally, Profund Advisors LLC purchased a new position in shares of Mineralys Therapeutics during the 2nd quarter valued at $164,000. Institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.